In multiple sclerosis (MS), lymphocyte—in particular B cell—transit between the central nervous system (CNS) and periphery may contribute to the maintenance of active disease. Pinpointing Ig class-switched B cells as key component of the immune axis thought to contribute to ongoing MS disease activity strengthens the rationale of current B cell–targeting therapeutic strategies and may lead to more targeted approaches. Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a wide range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. The cause of MS is unknown; however, it is believed to occur as a result of some combination of environmental factors such as infectious agents and genetics. There is similarity among Multiple Sclerosis, Neurodegenerative disorder, Acute disseminated encephalomyelitis (ADEM) and Mycoplasma Infectious Diseases It might have been misunderstand, misdiagnosed and over looked. Mycoplasma is oftenly misunderstand as virus, because mycoplasma is smallest bacteria and behaves like virus. However, the treatment and difficulty are quite different between mycoplasma and virus. It is important to know the correct cause of the illness. Mycoplasma is the bacteria not the virus. In the case of mycoplasma, there is the way to treat it. Mycoplasma Infectious Diseases is the systemic vasculitis/neuritis. It is not only pneumonia but also asthma, arthritis, nephritis, meningitis, encephalitis, dermatitis, pancreatitis, hepatitis, abnormalities in blood, so on. The concept of “Mycoplasma Infectious Diseases” is broad from acute to chronic phase with a variegated condition. Therefore, it is confusing and difficult to identify the mycoplasma-infected patient among those of incurable diseases, such as autoimmune diseases, a rheumatic disease, a nervous system disorder, and hematological disorders. Regrettably, conventional diagnostic system has been helpful only for pneumonia, although it is critical turning point to find variegated Mycoplasma Infectious Diseases at an early stage for performing an effective medical protocol. Fortunately, the cutting-edge technology based on the mycoplasma species-specific glycolipid-antigens, has made it possible to measure the amount of specific antibodies. The new technology provides a reliable marker to follow the state of Mycoplasma Infectious Diseases, monitoring the fluctuations of antibody titers. I would like to introduce the novel therapeutic strategy for Mycoplasma Infectious Diseases. It is important to establish diagnostic system to differentially diagnose them, and treat correctry following the state of infection precisely. The reliable diagnostics are necessary. The cutting-edge technology has made it possible to measure the specific antibodies. The new diagnostics for “Mycoplasma Infectious Diseases” make it possible to monitor by measuring tiny fluctuations of antibody titers from zero. The new measuring methods, IgM, IgG, and IgA antibody amonts, using the mycoplasma species-specific glycolipid-antigens, are already established. ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgM antibodies ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgG antibodies ・Anti-Mycoplasma pneumonie-specific lipid-antigen IgA antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgM antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgG antibodies ・Anti-Mycoplasma fermentans-specific lipid-antigen IgA antibodies
Posted on: Mon, 18 Aug 2014 11:23:42 +0000
Trending Topics
Recently Viewed Topics
© 2015